Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Drug discovery paradigms: past, present, future - a centennial symposium of the American Society for Pharmacology and Experimental Therapeutics.

Cavero I, Kaplan HR.

Expert Opin Drug Discov. 2008 Sep;3(9):1145-54. doi: 10.1517/17460441.3.9.1145.

PMID:
23506185
2.

In transition. Empowering your menopausal patients.

Kaplan HR, Abisla ML.

Adv Nurse Pract. 1997 Jun;5(6):28-33. Review. No abstract available.

PMID:
9459925
3.

Reduction of canine myocardial infarct size by CI-959, an inhibitor of inflammatory cell activation.

Burke SE, Wright CD, Potoczak RE, Boucher DM, Dodd GD, Taylor DG Jr, Kaplan HR.

J Cardiovasc Pharmacol. 1992 Oct;20(4):619-29.

PMID:
1280719
4.

Quinapril: overview of preclinical data.

Kaplan HR, Taylor DG, Olson SC.

Clin Cardiol. 1990 Jun;13(6 Suppl 7):VII6-12. Review.

5.

Quinapril--a preclinical review of the pharmacology, pharmacokinetics, and toxicology.

Kaplan HR, Taylor DG, Olson SC, Andrews LK.

Angiology. 1989 Apr;40(4 Pt 2):335-50. Review.

PMID:
2539761
6.

Pirmenol: preclinical pharmacology.

Kaplan HR, Mertz TE, Steffe TJ.

Angiology. 1988 Mar;39(3 Pt 2):281-92. Review.

PMID:
3281517
7.

Subclasses of cyclic AMP phosphodiesterase in cardiac muscle.

Weishaar RE, Kobylarz-Singer DC, Kaplan HR.

J Mol Cell Cardiol. 1987 Oct;19(10):1025-36.

PMID:
2830402
8.
9.

Preclinical pharmacology of pirmenol.

Kaplan HR, Mertz TE, Steffe TJ.

Am J Cardiol. 1987 Jun 15;59(16):2H-9H.

PMID:
3591710
10.

Pharmacology of bevantolol hydrochloride.

Kaplan HR.

Am J Cardiol. 1986 Nov 26;58(12):3E-7E.

PMID:
2878599
11.

Advances in antiarrhythmic drug therapy--changing concepts. Introduction.

Kaplan HR.

Fed Proc. 1986 Jul;45(8):2184-5. No abstract available.

PMID:
3720961
12.

Bevantolol hydrochloride--preclinical pharmacologic profile.

Kaplan HR.

Angiology. 1986 Mar;37(3 Pt 2):254-62.

PMID:
2871786
13.

New directions in antihypertensive drug therapy.

Kaplan HR, Cohen DM, Evans DB, Krause BR, Newton RS, Ryan MJ.

Prog Clin Biol Res. 1986;219:281-309. Review. No abstract available.

PMID:
2878440
14.

Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.

Weishaar RE, Kobylarz-Singer DC, Quade MM, Steffen RP, Kaplan HR.

J Cyclic Nucleotide Protein Phosphor Res. 1986-1987;11(7):513-27.

PMID:
2831259
15.

Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.

Roark WH, Tinney FJ, Cohen D, Essenburg AD, Kaplan HR.

J Med Chem. 1985 Sep;28(9):1291-5.

PMID:
2993618
16.

What a director of pharmacology looks for in a physiologist.

Kaplan HR.

Physiologist. 1984 Oct;27(5):356-7. No abstract available.

PMID:
6514823
17.

Antihypertensive profile of the angiotensin-converting enzyme inhibitors CI-906 and CI-907.

Ryan MJ, Boucher DM, Cohen DM, Olszewski BJ, Singer RM, Smith RD, Kaplan HR.

Fed Proc. 1984 Apr;43(5):1330-2.

PMID:
6323224
18.

CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.

Kaplan HR, Cohen DM, Essenburg AD, Major TC, Mertz TE, Ryan MJ.

Fed Proc. 1984 Apr;43(5):1326-9.

PMID:
6323223
19.

Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.

Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, Mertz TE, Olszewski BJ, Randolph AE, Singer RM, Kaplan HR.

J Pharmacol Exp Ther. 1984 Feb;228(2):312-8.

PMID:
6319675
21.

Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.

Blankley CJ, Bennett LR, Fleming RW, Smith RD, Tessman DK, Kaplan HR.

J Med Chem. 1983 Mar;26(3):403-11.

PMID:
6827558
22.

Survey of new antihypertensive drugs: 1982.

Kaplan HR, Ryan MJ, Singer RM, Cohen DM, Cygan RM.

Fed Proc. 1983 Feb;42(2):154-6.

PMID:
6822288
23.
25.

Derivatives of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline: effect of changes at positions 2 and 5 of the hexanoic acid portion.

Almquist RG, Crase J, Jennings-White C, Meyer RF, Hoefle ML, Smith RD, Essenburg AD, Kaplan HR.

J Med Chem. 1982 Nov;25(11):1292-9.

PMID:
6292422
26.

Angiotensin converting enzyme inhibitors: modifications of a tripeptide analogue.

Meyer RF, Essenburg AD, Smith RD, Kaplan HR.

J Med Chem. 1982 Aug;25(8):996-9.

PMID:
6288947
27.

Strategy for the discovery and development of a positive inotropic agent.

Evans DB, Weishaar RE, Kaplan HR.

Pharmacol Ther. 1982;16(3):303-30. Review. No abstract available.

PMID:
6127729
28.

Novel synthesis of (S)-1-[5-(benzoylamino)-1,4-dioxo-6-phenylhexyl]-L-proline and analogues: potent angiotensin converting enzyme inhibitors.

Meyer RF, Nicolaides ED, Tinney FJ, Lunney EA, Holmes A, Hoefle ML, Smith RD, Essenburg AD, Kaplan HR, Almquist RG.

J Med Chem. 1981 Aug;24(8):964-9.

PMID:
6173481
29.

Hypertension and antihypertensive drugs: introductory remarks.

Kaplan HR.

Fed Proc. 1981 Jun;40(8):2250-1. No abstract available.

PMID:
7238909
30.

Antihypertensive drugs: proposed sites and mechanisms of action.

Kaplan HR, Smith RD.

Fed Proc. 1981 Jun;40(8):2268-74. No abstract available.

PMID:
6113170
31.

Acute tolerance to prazosin in conscious hypertensive rats: involvement of the renin-angiotensin system.

Smith RD, Tessman DK, Kaplan HR.

J Pharmacol Exp Ther. 1981 May;217(2):397-405. No abstract available.

PMID:
7014831
32.

Synthesis and angiotensin-converting enzyme inhibitory activity of 3-(Mercaptomethyl)-2-oxo-1-pyrrolidineacetic acids and 3-(Mercaptomethyl)-2-oxo-1-piperidineacetic acids.

Klutchko S, Hoefle ML, Smith RD, Essenburg AD, Parker RB, Nemeth VL, Ryan MJ, Dugan DH, Kaplan HR.

J Med Chem. 1981 Jan;24(1):104-9.

PMID:
6259352
33.

CL-845 (pirmenol hydrochloride): a new orally effective long-acting antiarrhythmic agent.

Steffe TJ, Mertz TE, Hastings SG, Potoczak RE, Kaplan HR.

J Pharmacol Exp Ther. 1980 Jul;214(1):50-7. No abstract available.

PMID:
7391970
34.

Repeat abortions: blaming the victims.

Howe B, Kaplan HR, English C.

Am J Public Health. 1979 Dec;69(12):1242-6.

35.

Professionals and unionization: a study of two cohorts of physician housestaff.

Engel GV, Schulman ML, Patchel C, Kaplan HR.

Eval Health Prof. 1979 Sep;2(3):331-55. No abstract available.

PMID:
10243856
36.

Prazosin and phentolamine: comparative cardiovascular and autonomic profiles.

Commarato MA, Langley AE, Dugan DH, Lattime EC, Smith RD, Tessman DK, Kaplan HR.

Clin Exp Hypertens. 1978;1(2):191-217. No abstract available.

PMID:
39713
37.
38.

Levo-bunolol and propranolol: further evaluation of oral beta-blocking activity in conscious dogs.

Commarato MA, Giardino EC, Kopia GA, Kaplan HR.

Arch Int Pharmacodyn Ther. 1977 Apr;226(2):205-13.

PMID:
327960
39.
40.

Hemoglobin solution: a potential oxygen transporting plasma volume expander.

Kaplan HR, Murthy VS.

Fed Proc. 1975 May;34(6):1461-5.

PMID:
1126443
41.

Antiarrhythmic and general cardiovascular activity of the N,N-dimethylquaternary ammonium derivative of bunolol.

Kaplan HR, Barker JW, Dugan D, Fox J, Giardino E.

Arch Int Pharmacodyn Ther. 1974 Jan;207(1):28-43. No abstract available.

PMID:
4151048
42.

Glyceryl trinitrate and pentrinitrol (pentaerythritol trinitrate): comparative cardiovascular effects in dog, cat and rat by different routes of administration.

Commarato MA, Winbury MM, Kaplan HR.

J Pharmacol Exp Ther. 1973 Nov;187(2):300-7. No abstract available.

PMID:
4201273
43.
44.

Quindonium bromide: cardiac rate and rhythm disturbances in barbiturate. Anesthetized dogs.

Kaplan HR, La Sala SA.

J Pharmacol Exp Ther. 1972 Apr;181(1):98-107. No abstract available.

PMID:
5013159
45.

Bunolol metabolism by cell-free preparations of human liver: biosynthesis of dihydrobunolol.

Leinweber FJ, Greenough RC, Schwender CF, Kaplan HR, Di Carlo FJ.

Xenobiotica. 1972 Mar;2(2):191-202. No abstract available.

PMID:
4560367
46.

Direct evidence for a centrally-mediated hypotensive action of L-dopa in anesthetized dogs.

Kaplan HR, Barker JW, La Sala SA.

Eur J Pharmacol. 1972 Feb;17(2):273-8. No abstract available.

PMID:
4402097
47.

Oral -adrenoreceptor blocking activity of bunolol and its optical isomers.

Kaplan HR, Lasala SA, Robson RD.

Eur J Pharmacol. 1971 Oct;16(2):237-40. No abstract available.

PMID:
4405784
48.

Antiarrhythmic activity of bunolol, a new beta adrenergic blocking agent.

Kaplan HR, Robson RD.

J Pharmacol Exp Ther. 1970 Oct;175(1):168-77. No abstract available.

PMID:
4394302
49.

The cardiovascular pharmacology of bunolol, a new beta adrenergic blocking agent.

Robson RD, Kaplan HR.

J Pharmacol Exp Ther. 1970 Oct;175(1):157-67. No abstract available.

PMID:
4394301
50.

An investigation into the bradycardic effects of ST 155 [2-(2,6-dichlorophenylamino)-2-imidazoline HCl] in the anesthetized dog.

Robson RD, Kaplan HR, Laforce S.

J Pharmacol Exp Ther. 1969 Sep;169(1):120-31. No abstract available.

PMID:
4389918

Supplemental Content

Loading ...
Support Center